中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.026 seconds)

    Modified two-component gelation systems, methods of use and methods of manufacture
    11.
    发明授权
    Modified two-component gelation systems, methods of use and methods of manufacture 失效
    改进的双组分凝胶化系统，使用方法和制造方法

    公开(公告)号：US07732190B2

    公开(公告)日：2010-06-08

    申请号：US11496824

    申请日：2006-07-31

    Applicant: Eugene Michal ,  Olof Mikael Trollsas ,  Shubhayu Basu

    Inventor： Eugene Michal ,  Olof Mikael Trollsas ,  Shubhayu Basu

    IPC: A61K45/00 ,  C12M1/00 ,  A01N65/00 ,  A01N37/18 ,  A61K9/00 ,  A61K9/14 ,  A61K35/12 ,  A61F2/00

    CPC classification number: A61K47/34 ,  A61K9/0024 ,  A61K9/06 ,  A61K35/12 ,  A61K38/00 ,  A61L27/26 ,  A61L27/38 ,  A61L27/50 ,  A61K2300/00

    Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.

    Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。

    Extravascular neuromodulation to treat heart failure
    13.
    发明授权
    Extravascular neuromodulation to treat heart failure 有权
    血管内神经调节治疗心力衰竭

    公开(公告)号：US08983601B2

    公开(公告)日：2015-03-17

    申请号：US13405909

    申请日：2012-02-27

    Applicant: Kiyotaka Fukamachi ,  Alex Massiello ,  Mariko Kobayashi ,  Ray Dessoffy ,  Eugene Jung ,  Shubhayu Basu

    Inventor： Kiyotaka Fukamachi ,  Alex Massiello ,  Mariko Kobayashi ,  Ray Dessoffy ,  Eugene Jung ,  Shubhayu Basu

    IPC: A61N1/00 ,  A61N1/36 ,  A61N1/362

    CPC classification number: A61N1/36114 ,  A61N1/36139 ,  A61N1/3627

    Abstract: Treatment of heart failure in a patient by electrically modulating both the sympathetic and parasympathetic autonomic cardiac nerve fibers that innervate the patient's heart at an extravascular site in the pericardial space of the heart. The extravascular site is any suitable single location inside the chest cavity that carries both sympathetic and parasympathetic cardiac nerves such as the cardiac plexus or the pericardial transverse sinus or any two separate extravascular sites with one site carrying predominantly sympathetic cardiac nerves and the other site carrying predominantly parasympathetic cardiac nerves for electrically modulating the balance of autonomic cardiac nerve control. Physiologic inputs from a neuromodulation system's own sensors or from separate implanted or external cardiovascular hemodynamic sensor systems can be used for closed loop control over the balance of sympathetic and parasympathetic cardiac autonomic effects on the patient's cardiac function in real time response to chronic and transient physiologic needs.

    Abstract translation: 通过电动调节在心脏心包空间内的血管外位置支配患者心脏的交感神经和副交感神经自主神经纤维来治疗患者的心力衰竭。 血管外部位是胸腔内任何合适的单一位置，其携带交感神经和副交感神经，如心脏神经丛或心包横向窦或任何两个分离的血管外部位，一个位点主要携带交感神经，另一个位点主要携带 副交感神经，用于电调节自主神经控制的平衡。 来自神经调节系统的自身传感器或来自分离的植入或外部心血管血液动力学传感器系统的生理输入可用于闭环控制对交感神经和副交感神经心脏自主影响对患者心脏功能的平衡，实时响应慢性和短暂的生理需求 。

    EMBOLIC FILTER DEVICES, SYSTEMS, AND METHODS FOR CAPTURING EMBOLI DURING MEDICAL PROCEDURES
    15.
    发明申请
    EMBOLIC FILTER DEVICES, SYSTEMS, AND METHODS FOR CAPTURING EMBOLI DURING MEDICAL PROCEDURES 有权
    EMBOLIC过滤装置，系统和方法在医疗程序中捕获EMBOLI

    公开(公告)号：US20130245669A1

    公开(公告)日：2013-09-19

    申请号：US13756813

    申请日：2013-02-01

    Applicant: Shubhayu Basu ,  Stephen Ellis ,  Dave Dudzinski ,  Ryan S. Klatte

    Inventor： Shubhayu Basu ,  Stephen Ellis ,  Dave Dudzinski ,  Ryan S. Klatte

    IPC: A61F2/01

    CPC classification number: A61F2/013 ,  A61F2/01 ,  A61F2002/011 ,  A61F2230/0008 ,  A61F2230/0015 ,  A61F2230/005

    Abstract: One aspect of the present disclosure relates to an embolic filter device configured for placement in a blood vessel to capture emboli during a medical procedure. The embolic filter device can include an expandable frame member and a membrane. The expandable frame member can include a radial support member operably connected to first and second longitudinal struts, and an engaging portion extending between the first and second longitudinal struts. The engaging portion can be shaped and configured to temporarily receive, and sealingly mate with, a portion of an endovascular catheter during the medical procedure. The membrane can be securely connected to the frame member and define a collection chamber for captured emboli. The membrane can be configured to cover substantially all of the cross-sectional area of the blood vessel when the embolic filter device is deployed in the blood vessel.

    Abstract translation: 本公开的一个方面涉及一种栓塞过滤器装置，其被配置为放置在血管中以在医疗过程中捕获栓塞。 栓塞过滤装置可以包括可膨胀框架构件和膜。 可膨胀框架构件可以包括可操作地连接到第一和第二纵向支柱的径向支撑构件和在第一和第二纵向支柱之间延伸的接合部分。 接合部分可以成形和构造成在医疗过程期间暂时接收并密封地与血管内导管的一部分配合。 膜可以牢固地连接到框架构件并且限定用于捕获的栓塞的收集室。 当栓塞过滤器装置部署在血管中时，膜可以构造成覆盖血管的基本上所有的横截面面积。

    Needle catheter with an angled distal tip lumen
    16.
    发明授权
    Needle catheter with an angled distal tip lumen 有权
    针导管具有倾斜的远端尖端腔

    公开(公告)号：US08486022B2

    公开(公告)日：2013-07-16

    申请号：US12167791

    申请日：2008-07-03

    Applicant: Florian N. Ludwig ,  Shubhayu Basu

    Inventor： Florian N. Ludwig ,  Shubhayu Basu

    IPC: A61M5/178

    CPC classification number: A61M25/0068 ,  A61M25/0074 ,  A61M25/0084 ,  A61M2025/0081 ,  A61M2025/009

    Abstract: A needle catheter configured for injecting an agent into a wall of a patient's body cavity, which directs a needle from the distal tip of the catheter into the wall of the body cavity at an angle relative to the axis of the shaft. The resulting angled injection pathway improves the retention of the agent in the body cavity wall, while keeping a distal section of the catheter substantially perpendicular to the body cavity wall for optimal push against the tissue at the injection site.

    Abstract translation: 一种针导管，其构造成用于将药剂注射到患者体腔的壁中，其将针从导管的远侧末端引导到相对于轴的轴线成一定角度的体腔的壁中。 所产生的角度注射通道改善了药剂在体腔壁中的保留性，同时保持导管的远端部分基本上垂直于体腔壁，以最佳地推动注射部位处的组织。

    METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION
    17.
    发明申请
    METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION 有权
    改善心肌梗塞扩张的方法

    公开(公告)号：US20120059355A1

    公开(公告)日：2012-03-08

    申请号：US12877820

    申请日：2010-09-08

    Applicant: Shubhayu Basu ,  Randolf von Oepen ,  Eugene Michal ,  Florian Ludwig

    Inventor： Shubhayu Basu ,  Randolf von Oepen ,  Eugene Michal ,  Florian Ludwig

    IPC: A61B17/12 ,  A61M25/00

    CPC classification number: A61M25/1011 ,  A61B17/12045 ,  A61B17/12122 ,  A61B17/12136 ,  A61B17/12186 ,  A61B17/3478 ,  A61B2017/00243 ,  A61B2017/00495 ,  A61M25/003 ,  A61M2025/0092 ,  A61M2025/1052

    Abstract: A reinforcement region is formed within the myocardium by introducing a delivery device through a vessel wall to a treatment site within a myocardium. A biomaterial is then delivered to the treatment site as the delivery device is withdrawn from the treatment site to form the reinforcement regions. Formation of the reinforcement region may further include introducing a delivery device through a vessel wall to a region within a myocardium such that the delivery device is positioned within the myocardium substantially parallel to a wall of the myocardium. A biomaterial may be delivered into a space formed within the region by the delivery device. The reinforcement region may be formed around an infarct tissue region of a myocardium to reinforce the damaged tissue.

    Abstract translation: 通过将输送装置通过血管壁引导到心肌内的治疗部位，在心肌内形成增强区域。 然后当从处理部位取出输送装置以形成加强区域时，将生物材料输送到处理部位。 加强区域的形成可以进一步包括将输送装置通过血管壁引入心肌内的区域，使得输送装置位于基本上平行于心肌壁的心肌内。 生物材料可以通过输送装置输送到在该区域内形成的空间中。 加强区域可以围绕心肌的梗塞组织区域形成以加强受损组织。

    METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION
    18.
    发明申请
    METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION 有权
    改善心肌梗塞扩张的方法

    公开(公告)号：US20090022817A1

    公开(公告)日：2009-01-22

    申请号：US12016180

    申请日：2008-01-17

    Applicant: Eugene T. Michal ,  Shubhayu Basu ,  Alexander J. Sheehy ,  Francis G. Spinale ,  Rupak Mukherjee

    Inventor： Eugene T. Michal ,  Shubhayu Basu ,  Alexander J. Sheehy ,  Francis G. Spinale ,  Rupak Mukherjee

    IPC: A61K33/14 ,  C12N5/06 ,  A61P9/00

    CPC classification number: A61L27/26 ,  A61L27/20 ,  A61L27/22 ,  A61L27/3834 ,  A61L27/50 ,  A61L27/52 ,  A61L2300/418 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2430/20 ,  C08L5/04 ,  C08L89/00

    Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

    Abstract translation: 可以在足以引起心肌梗死扩张速率衰减的后心肌梗死区域中形成生物支架。 在心肌梗死后区域可进一步形成生物支架，引起左后壁壁厚度增加。 凝胶或生物支架可以由不同凝胶化系统的凝胶组分的混合物形成。 例如，生物支架可以通过混合至少两种不同的双组分凝胶化体系的至少两种不同组分形成第一混合物并通过混合至少两种不同组分（构成第一混合物的组分） 的至少两种不同的双组分凝胶化体系以形成第二混合物。

    Modified two-component gelation systems, methods of use and methods of manufacture
    19.
    发明申请
    Modified two-component gelation systems, methods of use and methods of manufacture 失效
    改进的双组分凝胶化系统，使用方法和制造方法

    公开(公告)号：US20080025943A1

    公开(公告)日：2008-01-31

    申请号：US11496824

    申请日：2006-07-31

    Applicant: Eugene Michal ,  Olof Mikael Trollsas ,  Shubhayu Basu

    Inventor： Eugene Michal ,  Olof Mikael Trollsas ,  Shubhayu Basu

    IPC: A61K38/22 ,  A61K38/19 ,  A61K38/18 ,  A61K35/14

    CPC classification number: A61K47/34 ,  A61K9/0024 ,  A61K9/06 ,  A61K35/12 ,  A61K38/00 ,  A61L27/26 ,  A61L27/38 ,  A61L27/50 ,  A61K2300/00

    Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.

    Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有在约6.5的pH下在第一缓冲液中组合的至少一个细胞粘附位点的物质。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送到治疗区域，例如心肌梗死后区域。

Patent Agency Ranking